Business article – November 19, 2026
Evaxion is shifting its strategy to concentrate on immuno-oncology. It will use its AI-Immunology platform to discover new cancer targets and develop cancer vaccines, and it will also make some changes to its organization.
Biotech Business – November 19, 2026
Asgard Therapeutics has been awarded a EUR 2.5 million grant from the European Innovation Council (EIC) Accelerator to move its lead program, AT-108, toward clinical trials in 2027. The grant also makes the company eligible for up to EUR 10 million in equity investment from the EIC Fund.
Clinical Trials – November 19, 2026
Cereno Scientific has dosed the first patient in EPIMODE, its global Phase IIb trial of the lead drug candidate CS1 in pulmonary arterial hypertension (PAH). This first dose formally launches the trial, which will evaluate CS1’s efficacy, optimal dose, safety, and tolerability, as well as its potential as a disease-modifying treatment.
MedTech Business – November 19, 2026
Clinical Laserthermia Systems (CLS) has signed a strategic partnership agreement with Germany’s Advanced Fiber Tools (AFT) to develop medical laser products for markets beyond its current focus on neurosurgery and urology.
Pharma Business – November 19, 2026
The US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Medivir’s MIV-711 for the treatment of osteogenesis imperfecta (OI), a rare disorder that causes fragile bones. If the drug is eventually approved, the designation could earn Medivir a Priority Review Voucher – an asset that has sold for between USD 180 million and USD 210 million in 2026.
In a new job – November 18, 2026
Sten Sörensen has resigned from the board of SynAct Pharma to focus on his executive responsibilities.

Opinion & debate
Clinical Trials – November 19, 2026
Cereno Scientific has dosed the first patient in EPIMODE, its global Phase IIb trial of the lead drug candidate CS1 in pulmonary arterial hypertension (PAH). This first dose formally launches the trial, which will evaluate CS1’s efficacy, optimal dose, safety, and tolerability, as well as its potential as a disease-modifying treatment.
Clinical Trials – November 17, 2026
Oncoinvent’s alpha radiopharmaceutical Radspherin has shown no treatment-related serious adverse events in the first interim safety analysis of its ongoing randomized Phase 2 trial in ovarian cancer.
Clinical Trials – November 10, 2026
Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, did not increase the risk of major cardiovascular events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial. With this result, the registrational SYNCHRONIZE program in obesity is complete.
Clinical Trials – November 9, 2026
Full results from Novo’s Phase 3 ZEUS trial confirm that the IL-6 inhibitor ziltivekimab did not reduce the risk of heart attack, stroke or cardiovascular death in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. The data were presented at the American Heart Association’s Scientific Sessions 2026 and published in the New England Journal of Medicine.
Clinical Trials – November 6, 2026
Boehringer Ingelheim has started Phase 2 development of BI 3034701, a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist partnered with Gubra, triggering a EUR 10 million milestone payment, Gubra said in its third-quarter trading statement. It is the second Gubra-partnered obesity program to reach Phase 2 this year, after AbbVie’s ABBV-295.
Clinical Trials – November 5, 2026
Finnish Herantis Pharma has extended the placebo-controlled period of its upcoming Phase II study of HER-096 in Parkinson’s disease. The company points to newly published evidence that smartphone-based motor assessments detect disease progression more sensitively than conventional clinical measures.
PharmaRelations
At PharmaRelations, we are looking for a Head of Patient Safety to play a key role in growing our Patient Safety department and business in Sweden and across the Nordics.
PharmaRelations
PharmaRelations is looking for a Nordic Head of Medical Device in Sweden to drive sales and profitable growth across the Swedish and Nordic Medical Device and MedTech markets through new business, long-term client relationships and a stronger market presence.
PharmaRelations
Do you have a strong network in the Finnish Life Science industry and enjoy turning relationships into business opportunities?
PharmaRelations
PharmaRelations is looking for a Head of Regulatory Affairs Development to lead and further develop our Regulatory Affairs services in the drug development space.
PharmaRelations
PharmaRelations is now looking for a Head of Clinical Operations in Denmark who wants to continue to build and develop our business in Denmark and south of Sweden (Öresundsregionen).
Karl Storz Endoskop Sverige AB
KARL STORZ är ett tyskt medicintekniskt företag som specialiserar sig på tillverkning och försäljning av endoskopisk utrustning och kirurgiska instrument. Företaget grundades 1945 i Tuttlingen av Dr. Karl Storz och har en lång historia av innovation inom medicinsk teknik.
In a new job – November 18, 2026
Jeppe Øvlesen has resigned as chair and member of the board of Cereno Scientific at his own request, effective immediately, a day after board member Johan Eriksson also left the board.
In a new job – November 16, 2026
Stockholm-based Karo Healthcare has appointed Sue Egstrand as CEO, effective January 1, 2027. She will lead the consumer healthcare company’s next phase of growth, with the goal of becoming one of Europe’s top five consumer healthcare players.
In a new job – November 11, 2026
Markus Rohrwild has stepped down as CEO of Danish Gubra, effective November 10, 2026. CFO Kristian Borbos and Zoë Johnson, Head of Gubra Ventures & Business Development, will take over as co-CEOs while keeping their current roles.
Career choice – November 15, 2026
From chemistry to drug discovery. Postdoc Gulshan Amrahova on molecular glues, letting your interests evolve, and building skills beyond your specialty.
Careers article – November 12, 2026
IRLAB Therapeutics is redirecting its resources toward revenue-generating partnerships for its existing project portfolio and plans to cut about ten positions, mainly in early-stage R&D. The company also says that new partnership agreements are now less likely to be signed before the end of 2026.
Careers article – October 20, 2026
Stamina, mentors, passion, and a life outside the lab. When Nordic Life Science profiled five leaders from across the region’s life science industry, from investors to a startup founder to two of its leading scientists, each shared advice for people starting out. Their answers had a lot in common.
Profiles in Business – October 18, 2026
Sesselja Ómarsdóttir has spent her career moving between academia and industry, from lichen chemistry in an Icelandic lab to leading Genis today. She talks about mentorship, curiosity, and what it means to keep one foot in each world.
Profiles in Business – October 12, 2026
Finnish Heidi Haikala has a foot in two life science worlds. As a cancer researcher she has established her own research group at the University of Helsinki and Tampere University, and she is also a co-founder of the startup company Solid IO.
Profiles in Business – October 4, 2026
Unbeknownst to her, Jessica Martinsson’s long and varied career in research and life sciences was preparing her for her newest and possibly most influential role.
Pharma Business – November 18, 2026
Biovica has received a second work order, worth about USD 150,000 (about SEK 1.4 million), from one of the world’s leading pharmaceutical companies under its recently expanded master services agreement.
Acquisition – November 17, 2026
Swedish Attana has agreed to acquire all shares in Finnish BioNavis, combining its QCM biosensor technology with BioNavis’ MP-SPR instruments to create a broader offering in analytical instruments for life science and materials science.
Pharma Business – November 17, 2026
The European Commission has approved Sobi’s Tryngolza (olezarsen) for adults with severe hypertriglyceridemia (sHTG) and triglyceride levels of at least 880 mg/dL, making it the first RNA-targeted therapy authorized in the EU for this patient group.
MedTech Business – November 12, 2026
Leeds Cancer Centre has treated the first patient using new reirradiation functionality in RaySearch Laboratories’ RayStation treatment planning system. The tools were developed over more than a decade of collaboration with Leeds Teaching Hospitals NHS Trust and the University of Leeds.
Agreement – November 4, 2026
Finnish Nightingale Health has signed two proteomics service agreements worth USD 1 million each, one with Alzheimer’s Research UK and one with medical research organization LifeArc. Both cover analysis of UK Biobank samples for research into neurodegenerative diseases.
Business Award – October 30, 2026
Copenhagen-based Evaxion has won the 2026 International Prix Galien Award for best digital health solution for its AI-Immunology platform. It is the first time a Danish company has received the prestigious award.
Biotech Business – November 18, 2026
Lytix Biopharma has raised NOK 80 million in a private placement and retail offering to prepare a registrational Phase III study of ruxotemitide in neoadjuvant melanoma.
Biotech Business – November 18, 2026
Xbrane Biopharma has received authorization from the Swedish Medical Products Agency to import medicinal products from outside the EU/EEA and to certify and release batches for supply within the EU. The approval is expected to simplify the supply chain for its ranibizumab biosimilar Ximluci/Lucamzi, including deliveries of finished product to the US.
Biotech Business – November 17, 2026
Commit Biologics has closed a USD 60 million (EUR 54 million) seed financing to take its first complement-powered immune engager, COM002, toward the clinic.
Science News – November 16, 2026
An international study led from Lund University shows that cancer cells reprogrammed into immune cells can help organize the immune system’s attack inside tumors. The findings, from experiments in mice, could pave the way for immunotherapies that work for more patients.
Funding – November 11, 2026
Novo has committed USD 200 million to the World Diabetes Foundation (WDF) for 2027–2036. The funding will support the foundation’s work to strengthen diabetes prevention and care in low- and middle-income countries.
Funding – October 30, 2026
Dr. Di Yu, co-founder of Uppsala-based Elicera Therapeutics, has received a grant of SEK 4 million from the Swedish Research Council to study how CAR-T cells can be designed to survive longer in the body and penetrate solid tumors more easily.
Upcoming events
This site uses cookies